NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Portfolio News / By Karina Tin November 13, 2023 NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® Read More »
Kallyope and Sosei Heptares Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Portfolio News / By Karina Tin November 10, 2023 Kallyope and Sosei Heptares Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases Read More »
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 8, 2023 Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Read More »
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Portfolio News / By Karina Tin November 6, 2023 ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates Read More »
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC Portfolio News / By Karina Tin November 3, 2023 RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, From Its Phase 2 Trial of FLX475 In Combination With A Checkpoint Inhibitor In Patients With Advanced NSCLC Read More »
A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Portfolio News / By Karina Tin November 2, 2023 A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Read More »
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights Portfolio News / By Karina Tin November 2, 2023 NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights Read More »
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Portfolio News / By Karina Tin November 1, 2023 Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Read More »
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / By Karina Tin October 26, 2023 Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
Circle Pharma Presented Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor at 2023 AACR-NCI-EORTC International Conference Portfolio News / By Karina Tin October 23, 2023 Circle Pharma Presented Compelling Data in Breast Cancer Treatment with First-In-Class Cyclin A/B Inhibitor at 2023 AACR-NCI-EORTC International Conference Read More »